{"organizations": [], "uuid": "32381585565081fe21e327f4b4389b5148e029ff", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eyenovia-advances-micropine-for-my/brief-eyenovia-advances-micropine-for-myopia-into-phase-iii-clinical-development-idUSASB0C6O3", "country": "US", "domain_rank": 408, "title": "BRIEF-Eyenovia Advances Micropine For Myopia Into Phase III Clinical Development", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-21T15:48:00.000+02:00", "replies_count": 0, "uuid": "32381585565081fe21e327f4b4389b5148e029ff"}, "author": "", "url": "https://www.reuters.com/article/brief-eyenovia-advances-micropine-for-my/brief-eyenovia-advances-micropine-for-myopia-into-phase-iii-clinical-development-idUSASB0C6O3", "ord_in_thread": 0, "title": "BRIEF-Eyenovia Advances Micropine For Myopia Into Phase III Clinical Development", "locations": [], "entities": {"persons": [{"name": "douglas fredrick", "sentiment": "none"}, {"name": "eyenovia", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters) - eyenovia inc", "sentiment": "none"}, {"name": "iii clinical development reuters staff", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "stanford", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "February 21, 2018 / 1:50 PM / Updated 6 minutes ago BRIEF-Eyenovia Advances Micropine For Myopia Into Phase III Clinical Development Reuters Staff 1 Min Read Feb 21 (Reuters) - Eyenovia Inc: * EYENOVIA ADVANCES MICROPINE FOR MYOPIA INTO PHASE III CLINICAL DEVELOPMENT AND APPOINTS STANFORD PROFESSOR DR. DOUGLAS FREDRICK TO ITS SCIENTIFIC ADVISORY BOARD AND MYOPIA PROGRAM STEERING COMMITTEE * EYENOVIA INC - MICROPINE PHASE III TRIAL FOR MYOPIA IS PLANNED TO START IN FIRST HALF OF 2019 * EYENOVIA INC - EYENOVIA HAS RECEIVED FEEDBACK THAT ONLY ONE PHASE III PIVOTAL STUDY WILL BE REQUIRED FOR REGISTRATION INSTEAD OF TWO TRIALS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-21T15:48:00.000+02:00", "crawled": "2018-02-21T16:01:58.001+02:00", "highlightTitle": ""}